期刊文献+

造血干细胞移植与骨髓增生异常综合征:现状与展望 被引量:1

原文传递
导出
摘要 骨髓增生异常综合征(MDS)是一组以骨髓髓细胞发育异常和无效造血、外周血细胞减少以及具有向急性髓系白血病(AML)转变风险为特征的克隆性造血细胞疾病,是二组异质性很高的疾病,其异质性表现在血细胞减少及严重程度、骨髓增生及原始细胞增多、疾病进展向AML转化的比率、总生存期以及对治疗的反应等方面。MDS是老年性疾病,随年龄增长其发病率逐渐增高,中位发病年龄约为70岁。根据SEER(surveillanceepidemiol—ogyandendresults),校正年龄的年发病率为3.4/100000人。国内尚未见准确的统计数据。
作者 张东华
出处 《临床血液学杂志》 CAS 2011年第6期635-637,共3页 Journal of Clinical Hematology
  • 相关文献

参考文献10

  • 1MA X, DOES M, RAZA A, et al. Myelodysplastic syndromes: incidence and survival in the United States[J]. Cancer, 2007,109:1536-- 1542.
  • 2徐泽锋,于明华,张悦,秦铁军,肖志坚.原始细胞不增高的骨髓增生异常综合征患者按WHO标准诊断分型的回顾性分析[J].中华内科杂志,2009,48(8):678-680. 被引量:2
  • 3GIRALT S A, HOROWITZ M,WEISDORF D, et al. Review of stem-cell transplantation for myelodysplas- tie syndromes in older patient in the context of the decision memo for allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome emanating from the centers for medicare and medicaid services[J]. J Clin Oncol,2011,29:566-572.
  • 4GARCIA-MANERO G, FENAUX F. Hypomethylating agents and other novel strategies in myelodysplastic syndromes[J].J Clin Oneol, 2011,29:516 - 523.
  • 5DEEG H J, Hematopoietic cell transplantation for rnyelodysplastic syndrome and myeloproliferative disorders[M]// APPELBAUM F R, FORMAN S J, NEGRIN R S, et al. Thomasr hematopoietic celltransplantation. 4th edition. Wiley-Blackwell, 2009: 830-830.
  • 6DEEG H J, APPELBAUM F R. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome[J]. Leukemia Res, 2000,24 :653 - 663.
  • 7DEEG H J,SHULMAN H M,ANDERSON J E, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age[J]. Blood, 2000,95 : 1188-- 1194.
  • 8LIM Z Y, BRAND R, MARTINO R, et al. Allogeneic hematop0ietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia[J]. J Clin Oncol, 2009,28:4Q5--411.
  • 9HORWITZ M E. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia,myelodysplastic syndrome and acute lymphoid leukemia[J]. Curr Opin Oncol, 2011,23 .. 197- 202.
  • 10CUTLER C. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome [J]. Hematology Am Soc Hematol Educ Program, 2010, 2010:325-329.

二级参考文献5

  • 1Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 2007,31:727-736.
  • 2Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008 : 88-107.
  • 3Schiffer CA. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Semin Hematol,2008,45:3-7.
  • 4Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia,2007,21 : 668 -677.
  • 5Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance ( ICUS ) versus low risk MDS : the diagnostic interface. Leuk Res ,2007,31 : 1461-1468.

共引文献1

同被引文献16

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部